Indaptus Therapeutics Files 8-K

Ticker: INDP · Form: 8-K · Filed: Sep 4, 2025 · CIK: 1857044

Indaptus Therapeutics, INC. 8-K Filing Summary
FieldDetail
CompanyIndaptus Therapeutics, INC. (INDP)
Form Type8-K
Filed DateSep 4, 2025
Risk Levellow
Pages1
Reading Time2 min
Key Dollar Amounts$0.01
Sentimentneutral

Sentiment: neutral

Topics: 8-K, corporate-filing, financials

TL;DR

Indaptus Therapeutics filed an 8-K on Sept 4, 2025. No major news, just routine filings.

AI Summary

Indaptus Therapeutics, Inc. filed an 8-K on September 4, 2025, reporting on other events and financial statements. The company, formerly known as Intec Parent Inc. until April 14, 2021, is incorporated in Delaware and headquartered in New York City.

Why It Matters

This filing provides an update on the company's corporate events and financial reporting, which is crucial for investors to stay informed about the company's status.

Risk Assessment

Risk Level: low — The filing is a routine 8-K report and does not contain any new material information that would immediately impact the company's risk profile.

Key Numbers

Key Players & Entities

FAQ

What is the primary purpose of this 8-K filing?

This 8-K filing is to report on 'Other Events' and 'Financial Statements and Exhibits' as of September 4, 2025.

When did Indaptus Therapeutics, Inc. change its name?

The company's name was changed from Intec Parent Inc. on April 14, 2021.

Where is Indaptus Therapeutics, Inc. headquartered?

The company's principal executive offices are located at 3 Columbus Circle, 15th Floor, New York, NY 10019.

What is the company's Standard Industrial Classification (SIC) code?

The SIC code for Indaptus Therapeutics, Inc. is 2834, which corresponds to Pharmaceutical Preparations.

What is the SEC file number for Indaptus Therapeutics, Inc.?

The SEC file number for Indaptus Therapeutics, Inc. is 001-40652.

Filing Stats: 430 words · 2 min read · ~1 pages · Grade level 10.4 · Accepted 2025-09-04 16:01:33

Key Financial Figures

Filing Documents

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: September 4, 2025 INDAPTUS THERAPEUTICS, INC. By: /s/ Nir Sassi Name: Nir Sassi Title: Chief Financial Officer

View Full Filing

View this 8-K filing on SEC EDGAR

View on Read The Filing